Key Highlights

  • Neurotech International (ASX:NTI) has secured binding commitments for approximately $4.5 million through a placement.
  • Funds will primarily support the Phase III double-blind, placebo-controlled NTI164 trial in children with Autism Spectrum Disorder.
  • The capital raising is expected to provide funding through to topline clinical data readout based on current plans and budgets.
  • The placement received support from existing and new institutional and sophisticated investors.

Neurotech International Ltd (ASX:NTI) has announced binding commitments to raise approximately $4.5 million through a placement aimed at advancing the company’s clinical development strategy for NTI164, its proprietary cannabinoid-based therapy targeting paediatric neurological disorders.

The placement involves approximately 321.4 million new fully paid ordinary shares issued at $0.014 per share. The capital raising was supported by existing shareholders as well as new institutional and sophisticated investors, providing funding for the next stage of Neurotech’s development pathway.

The company stated that the proceeds, together with existing cash reserves, are expected to fund operations through to topline data readout from the Phase III NTI164 Autism Spectrum Disorder (ASD) clinical trial.

Funding Supports Phase III ASD Clinical Trial

The majority of funds raised will be allocated toward Neurotech’s Phase III double-blind, placebo-controlled clinical trial evaluating NTI164 in children with Autism Spectrum Disorder.

The trial represents a key development milestone for the company as it seeks to generate further clinical evidence supporting NTI164’s potential application in ASD management.

Neurotech has previously completed Phase I/II and Phase II/III clinical trials across ASD and other paediatric neurological conditions, including PANDAS/PANS and Rett Syndrome. The company has reported clinically meaningful outcomes from earlier studies, although the Phase III trial remains subject to completion and regulatory assessment.

NTI164 Therapy Development Strategy

NTI164 is a proprietary, GMP-grade formulation containing CBDA-rich extracts and selected minor cannabinoids. Neurotech is developing the therapy based on research into neuroinflammatory signalling, immune regulation and biological pathways associated with neurodevelopmental disorders.

The company’s broader strategy focuses on developing treatments for paediatric neurological conditions where significant unmet medical needs remain.

The Phase III ASD programme is designed to further evaluate NTI164 through a controlled clinical framework, with the objective of supporting future regulatory and commercialisation discussions if successful outcomes are achieved.

Placement Structure and Investor Participation

The placement will involve approximately 321.4 million shares issued in two tranches. The first tranche represents approximately $4.1 million and includes shares issued under the company’s existing placement capacity.

The second tranche, valued at approximately $0.4 million, is subject to shareholder approval at a future general meeting.

Settlement of the first tranche is expected in August 2026, while the second tranche is expected to proceed following shareholder approval. The placement was managed by Taylor Collison Limited and Canary Capital Pty Ltd as joint lead managers.

The joint lead managers will receive management and selling fees, with additional options subject to shareholder approval as part of the consideration for their services.

Biopharmaceutical Market Context

Clinical-stage biotechnology companies often require significant capital investment to progress therapies through advanced clinical trials and regulatory pathways. Funding availability can influence the pace of research programmes, trial execution and preparation for potential commercialisation.

Neurotech’s capital raising provides resources to continue advancing NTI164 while supporting regulatory activities and corporate requirements. The company remains focused on generating clinical data that may inform future development decisions.

Future Development Pathway for Neurotech

Neurotech’s immediate focus remains the execution of its Phase III ASD clinical trial and delivery of topline results. The company’s progress will depend on clinical outcomes, regulatory requirements, manufacturing capabilities and future commercial considerations.

The completion of the placement provides financial support for the next stage of NTI164 development as Neurotech continues evaluating its potential role in addressing paediatric neurological disorders.

Conclusion

Neurotech International (ASX:NTI) has strengthened its funding position with a $4.5 million placement to support the advancement of its NTI164 clinical development programme. The funds are expected to assist the company through the Phase III ASD trial and toward topline data readout, representing an important milestone in its broader strategy. Future progress will depend on clinical results, regulatory processes and the company’s ability to advance NTI164 toward potential commercialisation.

Q1: What is Neurotech International (ASX:NTI)?
A: Neurotech International is an Australian clinical-stage biopharmaceutical company focused on developing treatments for paediatric neurological disorders.

Q2: How much capital did Neurotech International raise?
A: Neurotech secured binding commitments for approximately $4.5 million through a placement of new ordinary shares.

Q3: What will the placement funds be used for?
A: The funds will primarily support the Phase III NTI164 Autism Spectrum Disorder clinical trial, regulatory activities, working capital and placement costs.

Q4: What is NTI164?
A: NTI164 is Neurotech’s proprietary GMP-grade cannabinoid-based formulation containing CBDA-rich extracts and selected minor cannabinoids.

Q5: What is the purpose of the NTI164 Phase III trial?
A: The Phase III trial is designed to evaluate NTI164 in children with Autism Spectrum Disorder using a double-blind, placebo-controlled clinical study format.